Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics (BEAM) reported updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) presented at the 2026 European Respiratory Society Congress.
As of August 17, 2026, 38 patients had received BEAM-302, with efficacy data presented from 29 single-dose patients across lung (Part A) and liver (Part B) cohorts. At the 60 mg dose, mean steady-state total AAT rose from 5.0 µM to 14.4 µM in Part A and from 4.7 µM to 13.5 µM in Part B, exceeding the 11 µM protective threshold, with functional AAT levels increasing dose-dependently and durably. Circulating mutant Z-AAT fell by 84% in both 60 mg cohorts, with corresponding reductions in toxic Z-polymers and dose-proportionate decreases in human neutrophil elastase activity.
Safety remained acceptable, with mostly mild-to-moderate infusion-related reactions in 41% of patients and transient liver enzyme elevations, including one Grade 3 ALT/AST event without bilirubin increase or treatment. Newly produced corrected M-AAT reached 93% of circulating AAT at steady state. Beam has begun dosing a global pivotal cohort using 60 mg and plans to pursue a U.S. accelerated approval pathway based on 12‑month AAT biomarker endpoints.
Beam Therapeutics (Nasdaq: BEAM) announced the appointment of Eric Foster as chief commercial officer, responsible for leading its commercial organization and strategy as multiple precision genetic medicine candidates, including risto-cel, advance toward potential launches, with a targeted potential launch of risto-cel in 2027.
Foster brings more than 25 years of commercial leadership experience in biotechnology and specialty pharmaceuticals. He previously served as CCO at Ardelyx, U.S. general manager at Amgen after its acquisition of Horizon Therapeutics, and led Horizon franchises generating $2.75 billion in net sales revenue, with earlier senior roles at GlaxoSmithKline and Johnson & Johnson.
Beam Therapeutics (Nasdaq: BEAM) announced that its management will take part in fireside chats at three investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, Citi’s Biopharma Back to School Conference on September 9 in New York, and Cantor Fitzgerald Global Healthcare Conference 2026 on September 10 in New York. Live webcasts and 60-day archives will be available in the investor section of Beam’s website.
Beam Therapeutics (Nasdaq: BEAM) reported second quarter 2026 net loss of $122.7 million ($1.18/share) on license and collaboration revenue of $0.5 million, with R&D expenses of $95.1 million and G&A expenses of $31.9 million. Cash, cash equivalents and marketable securities were $1.15 billion at June 30, 2026, and the company expects its cash plus an additional $200 million from its Sixth Street facility to fund operations into mid‑2029.
Operationally, Beam dosed the first patient in the global pivotal cohort of its Phase 1/2 BEAM‑302 trial in AATD, completed dosing of all adult and adolescent patients in the BEACON trial of risto‑cel in SCD, and began clinical start‑up for BEAM‑304 in PKU after U.S. IND clearance. Initial BEAM‑301 data in GSDIa and updated BEACON data are expected in 2026, with a potential risto‑cel BLA submission as early as year‑end 2026.
Beam Therapeutics (Nasdaq: BEAM) will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD) in a late-breaking oral session at the European Respiratory Society (ERS) Congress 2026, held September 5–9, 2026 in Barcelona, Spain. BEAM-302 is described by Beam as its lead genetic disease program, a liver-targeting base-editing therapy intended to address both lung and liver manifestations of AATD by restoring AAT levels and function while eliminating toxic Z-AAT.
The late-breaking presentation, titled “First-in-Human in vivo Gene Editing for Severe Alpha-1 Antitrypsin Deficiency (AATD): Initial Data from the Phase 1/2 Study of BEAM-302”, is scheduled in the session “Understanding Treatment Response in Airway Diseases: from Mechanisms to Clinical Biomarkers” on Tuesday, September 8, 2026, from 9:30–10:45 a.m. CEST, and will be delivered by John Hurst, M.D., Ph.D., University College London. Beam also plans an investor conference call and webcast on Tuesday, September 8, 2026, at 7:00 a.m. ET, accessible via the Events section of its website, with a replay available afterward.
Beam Therapeutics (Nasdaq: BEAM) received U.S. FDA clearance of its IND application for BEAM-304, an in vivo base-editing candidate for treating phenylketonuria (PKU).
BEAM-304 uses lipid nanoparticle delivery to correct PAH gene mutations, with preclinical mouse data showing normalization of plasma phenylalanine at clinically relevant doses. A Phase 1/2 trial in PKU patients is planned.
Beam Therapeutics (Nasdaq: BEAM) presented updated Phase 1/2 data for its base-editing candidate BEAM-302 in alpha-1 antitrypsin deficiency (AATD) at the ATS 2026 conference.
The update covers single-dose cohort safety, durability of efficacy and reduced human neutrophil elastase activity, and outlines plans for an FDA accelerated approval path with a pivotal expansion starting in 2H 2026.
Beam Therapeutics (NASDAQ: BEAM) became an inaugural industry sponsor of AlphaDetect, a nonprofit powered by the Alpha-1 Foundation. The sponsorship supports scaling routine, targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in liver and lung disease patients through free genetic testing, provider support, and enhanced detection protocols aligned with clinical guidelines.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:30 a.m. ET in New York.
A live webcast will stream via the investor section of www.beamtx.com and remain archived for 60 days.
Beam Therapeutics (Nasdaq: BEAM) will present updated biomarker data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease at EHA2026, June 11-14, 2026, in Stockholm.
Presentations highlight red blood cell health, sickling and rheology parameters, and fetal hemoglobin correlations.